Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | NPC1 | O15118 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | TP53 | P04637 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 1/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | CASP1 | P29466 | 1/20 | 0.70 |
| ▸ | CASP7 | P55210 | 1/20 | 0.70 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | GFER | P55789 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | CTSL | P07711 | 1/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12799147 | 0.97 | NPC1 (0.71) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| SCHEMBL2064358 | 0.97 | NPC1 (0.71) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| Hydrochloric Acid SCHEMBL22031645 | 0.97 | MAPT (0.68) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| Hydrochloric Acid SCHEMBL2159983 | 0.95 | NPC1 (0.69) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| SCHEMBL16404482 | 0.95 | MAPT (0.64) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| SCHEMBL5760520 | 0.91 | NPC1 (0.65) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| SCHEMBL10373626 | 0.89 | MAPT (0.77) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| SCHEMBL12069817 | 0.87 | MAPT (0.58) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| SCHEMBL19648939 | 0.87 | MAPT (0.59) | ALDH1A1MAPTNPC1RAB9ATP53 | |
| SCHEMBL29709399 | 0.86 | MAPT (0.56) | ALDH1A1MAPTNPC1RAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12188139-B2 | Alternating current electrolysis for use in organic synthesis | WAYNE STATE UNIVERSITY (US) | 2025-01-07 | — | — | US | disclosed |
| CN-114656389-B | Synthesis method of 1-phenylpyrrolidine | 河南大学 | 2023-12-15 | — | — | CN | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230091947-A1 | ALTERNATING CURRENT ELECTROLYSIS FOR USE IN ORGANIC SYNTHESIS | WAYNE STATE UNIVERSITY (US) | 2023-03-23 | — | — | US | disclosed |
| US-11499238-B2 | Alternating current electrolysis for use in organic synthesis | WAYNE STATE UNIVERSITY (US) | 2022-11-15 | — | — | US | disclosed |
| CN-114656389-A | Synthesis method of 1-phenylpyrrolidine | 河南大学 | 2022-06-24 | — | — | CN | disclosed |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210207274-A1 | ALTERNATING CURRENT ELECTROLYSIS FOR USE IN ORGANIC SYNTHESIS | WAYNE STATE UNIVERSITY (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210207274-A1 | ALTERNATING CURRENT ELECTROLYSIS FOR USE IN ORGANIC SYNTHESIS | WAYNE STATE UNIVERSITY (US) | 2021-07-08 | — | — | US | disclosed |
| CN-109988091-A | A kind of preparation method of group with imine moiety | 苏州大学 | 2019-07-09 | — | — | CN | disclosed |
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB (DK) | 2010-07-15 | — | — | US | disclosed |
| US-7732473-B2 | Compounds with nootropic action, their preparation, pharmaceutical compositions containing them, and use thereof | NEUROTUNE AG (CH) | 2010-06-08 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| EP-2155669-A1 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-02-24 | — | — | EP | disclosed |
| EP-2155671-A2 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-02-24 | — | — | EP | disclosed |
| US-20090163565-A1 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof | FARINA CARLO | 2009-06-25 | — | — | US | disclosed |
| WO-2008148799-A1 | NEW DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008148801-A2 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | NSAB, FILIAL OF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2008-12-11 | — | — | WO | disclosed |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-1990009801-A1 | 4-HYDROXYTHIAZOLES AS 5-LIPOXYGENASE INHIBITORS | ABBOTT LABORATORIES (US) | 1990-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179211-A1 | DISUBSTITUTED PHENYLPYRROLIDINES AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION | PNMT, DBH, SLC6A2 | ALDH1A1 1996/4885MAPT 297/4885NPC1 2286/4885 |
| US-11358932-B2 | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | GBA1, UGCG, GBA2 | ALDH1A1 1011/4885MAPT 3882/4885NPC1 98/4885 |
| US-20090163565-A1 | Compounds with nootropic action, their preperation, pharmaceutical compositions containing them, and use thereof | OPRL1, GRIN3B, GRIN3A | ALDH1A1 1813/4885MAPT 1530/4885NPC1 1386/4885 |
| US-20060223760-A1 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | MCL1, BRCA1, IDO1 | ALDH1A1 989/4885MAPT 4236/4885NPC1 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.